IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

Background: IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia. Its pathogenesis involves higher expression of galactose-deficient IgA1 (Gd-IgA1) and dysregulated intestinal ...

Background: Increasing evidence shows that Angptl4 affects proteinuria in podocytes injured kidney disease, however, whether there is a relationship between Angptl4 and IgA nephropathy (IgAN) has not ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

导读近年来，IgA肾病(IgAN)相关的临床研究不断取得进展，新的治疗策略也不断涌现。2025年国际肾脏病学会(ISN)世界肾脏病大会(WCN)于2025年2月6-9日在印度新德里举行。此次大会由ISN组织和印度肾脏病学会联合举办，是国际上备受瞩目的 ...

导读近年来，IgA肾病(IgAN)相关的临床研究不断取得进展，新的治疗策略也不断涌现。2025年国际肾脏病学会(ISN)世界肾脏病大会(WCN)于2025年2月6-9日在印度新德里举行。此次大会由ISN组织和印度肾脏病学会联合举办，是国际上备受瞩目的 ...

The registrational Phase III study is a multicenter, open-label, single arm study in Japanese patients with IgA nephropathy, and is planned to confirm the efficacy and safety of sparsentan in ...

The FDA has given breakthrough therapy designation to OMS721, a new treatment for the rare kidney disease immunoglobulin A (IgA) nephropathy. The news is a major boost for Seattle-based Omeros ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...